Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Subcutaneous and Intravenous Anifrolumab in Healthy Chinese Participants
NCT06662123Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of anifrolumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under the serum concentration-time curve extrapolated to infinity, Maximum observed serum concentration and 8 more. Started Oct 2024; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06662123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662123.